Slide-Deoxyribonucleic Acid (DNA)-Sequencing For Copy Number Mapping Market Report 2026

Slide-Deoxyribonucleic Acid (DNA)-Sequencing For Copy Number Mapping Market Overview

• Slide-Deoxyribonucleic Acid (DNA)-Sequencing For Copy Number Mapping market size has reached to $0.38 billion in 2025 • Expected to grow to $0.75 billion in 2030 at a compound annual growth rate (CAGR) of 14.8% • Growth Driver: Growing Demand For Precision Medicine Fueling The Growth Of The Market Due To Increasing Need For Patient-Specific Diagnosis And Targeted Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Slide-Deoxyribonucleic Acid (DNA)-Sequencing For Copy Number Mapping Market?

Slide-deoxyribonucleic acid (DNA) sequencing for copy number mapping is a laboratory technique that sequences DNA on microscope slides to identify variations in the number of copies of specific genomic regions. It helps to detect duplications, deletions, or amplifications in the genome, which helps in understanding genetic disorders, cancer progression, and other genomic abnormalities. This method allows high-resolution, spatially precise analysis of DNA, enabling researchers to map genomic changes directly on tissue samples. The main workflow of slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping include sample preparation, sequencing and imaging, and data analysis and interpretation. Sample preparation is the process of treating and processing a biological, chemical, or environmental sample to make it suitable for analysis or testing. The various product types include instruments, consumables, software, and services and are compatible with sample types such as fresh frozen (FF) tissues, formalin-fixed paraffin-embedded (FFPE) tissues, and organoids and 3D cell cultures, and cover workflows including sample preparation, sequencing and imaging, and data analysis and interpretation. The key applications of cancer genomics, genetic disease research, prenatal diagnostics, and other applications, while the end-use includes hospitals and diagnostic centers, academic and research institutes, biotechnology and pharmaceutical companies, contract research organizations, and genomic laboratories.

What Is The Slide-Deoxyribonucleic Acid (DNA)-Sequencing For Copy Number Mapping Market Growth Forecast?

The slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market size is expected to see rapid growth in the next few years. It will grow to $0.75 billion in 2030 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to integration with ai-driven variant calling, demand for high-throughput imaging, adoption of single-molecule sequencing, growth of personalized medicine applications, expansion of genomic laboratories in emerging markets. Major trends in the forecast period include high-resolution dna mapping, single-cell sequencing integration, automated slide processing, spatial genomics analytics, predictive genomic variation modeling.

Global Slide-Deoxyribonucleic Acid (DNA)-Sequencing For Copy Number Mapping Market Segmentation

1) By Workflow: Sample Preparation, Sequencing And Imaging, Data Analysis And Interpretation 2) By Product Type: Instruments, Consumables, Software, Services 3) By Sample Type: Fresh Frozen (FF) Tissues, Formalin-Fixed Paraffin-Embedded (FFPE) Tissues, Organoids And 3D Cell Cultures 4) By Application: Cancer Genomics, Genetic Disease Research, Prenatal Diagnostics, Other Applications 5) By End User: Hospitals And Diagnostic Centers, Academic And Research Institutes, Biotechnology And Pharmaceutical Companies, Contract Research Organizations, Genomic Laboratories Subsegments: 1) By Sample Preparation: Deoxyribonucleic Acid Extraction, Library Preparation, Fragmentation And Shearing, Quality Control And Quantification 2) By Sequencing And Imaging: Fluorescent Labeling Sequencing, Optical Mapping Sequencing, Single Molecule Sequencing, High Throughput Imaging 3) By Data Analysis And Interpretation: Alignment And Mapping, Variant Calling, Copy Number Variation Analysis, Visualization And Reporting

What Are The Drivers Of The Slide-Deoxyribonucleic Acid (DNA)-Sequencing For Copy Number Mapping Market?

The growing demand for precision medicine is expected to propel the growth of the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market going forward. Precision medicine refers to a healthcare approach that uses individual genetic and molecular characteristics to guide diagnosis and treatment decisions for improved clinical outcomes. The rise in adoption of precision medicine is increasing due to the rising global burden of complex and chronic diseases that require highly specific and individualized treatment strategies. Slide-deoxyribonucleic acid (DNA) sequencing for copy number mapping supports the growing demand for precision medicine by enabling detailed analysis of genomic variations that inform patient-specific diagnosis and treatment. It facilitates targeted therapies, enhances risk assessment, and improves clinical decision-making for more personalized and effective healthcare. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based educational and advocacy organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. Therefore, the growing demand for precision medicine is driving the growth of the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping industry. The increasing prevalence of genetic disorders is expected to propel the growth of the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market going forward. Genetic disorders refer to diseases or conditions caused by abnormalities in an individual’s DNA, including mutations, deletions, or chromosomal changes that affect normal biological functions. The rise in genetic disorders due to increasing awareness and advanced diagnostic capabilities is leading to more cases being identified, enabling earlier detection and management of inherited conditions. Slide-deoxyribonucleic acid (DNA) sequencing for copy number mapping supports the management of genetic disorders by enabling precise detection of genomic variations, including duplications and deletions, that contribute to disease. It facilitates early diagnosis, guides personalized treatment strategies, and enhances monitoring of disease progression for improved patient outcomes. For instance, in May 2024, according to the National Health Service, a UK-based government department, there are 17,000 people living with sickle cell disease, an inherited genetic blood disorder, with around 250 new cases diagnosed each year. Therefore, the increasing prevalence of genetic disorders is driving the growth of the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping industry. The rising healthcare expenditure is expected to propel the growth of the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market going forward. Healthcare expenditure refers to the total amount of financial resources spent on healthcare services, including medical treatments, hospital care, medications, and public health initiatives, by governments, businesses, and individuals. The increasing demand for healthcare expenditure is due to the rising prevalence of chronic diseases, which require long-term and costly treatments. Rising healthcare expenditure enhances slide–deoxyribonucleic acid (DNA) sequencing for copy number mapping by enabling greater investment in advanced genomic technologies, infrastructure, and skilled personnel. It supports wider adoption in clinical settings, accelerates research and diagnostic applications, and improves accessibility to personalized genetic disorder management. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Therefore, the rising healthcare expenditure is driving the growth of the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping industry.

Key Players In The Global Slide-Deoxyribonucleic Acid (DNA)-Sequencing For Copy Number Mapping Market

Major companies operating in the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market are Thermo Fisher Scientific, Becton Dickinson Company (BD), Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bruker Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., 10x Genomics Inc., BGI Genomics Co. Ltd., Takara Bio Inc., Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Fluidigm Corporation, Roche Sequencing Solutions, Mission Bio Inc., Twist Bioscience Corp., Genapsys Inc., Phase Genomics Inc., Singular Genomics Systems Inc.

Regional Insights

North America was the largest region in the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Slide-Deoxyribonucleic Acid (DNA)-Sequencing For Copy Number Mapping Market?

The slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market consists of revenues earned by entities by providing services such as spatial transcriptomics analysis, copy number variation analysis services, bioinformatics data analysis, library preparation, sample processing, tissue slide preparation, genomic data interpretation, and research consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market also includes sales of DNA sequencing instruments, spatial sequencing platforms, tissue slide arrays, microarray slides, library preparation kits, DNA extraction kits, reagents and assay kits, sequencing flow cells, microfluidic chips, imaging systems, and sample preservation kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Slide-Deoxyribonucleic Acid (DNA)-Sequencing For Copy Number Mapping Market Report 2026?

The slide-deoxyribonucleic acid (dna)-sequencing for copy number mapping market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the slide-deoxyribonucleic acid (dna)-sequencing for copy number mapping industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.